Streetbeat News

CLYM

Climb Bio, Inc.

Industry

Biotechnology

Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Climb Bio announced its Q3 2024 financial results and business updates, including the appointment of Douglas Williams, Ph.D. as Chair of the Board, FDA clearance for an IND for systemic lupus erythematosus, and the addition of Gary Hao, Ph.D. to the management team.

Portfolio Pulse from

November 12, 2024 | 9:15 pm

Climb Bio, Inc. (Nasdaq: CLYM) has appointed Douglas E. Williams, Ph.D., as the new Chair of its Board of Directors. Dr. Williams brings over 30 years of experience in the biotechnology sector, having contributed to the development of several significant drugs and led companies through successful mergers.

Portfolio Pulse from

November 11, 2024 | 12:15 pm

Climb Bio has completed its transition to focus on immune-mediated diseases and expects its cash runway to last through 2027, enabling the delivery of key value inflection points.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 11:44 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.